Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1 - From blood spot to screening result
暂无分享,去创建一个
Luciano Vittozzi | Georg F. Hoffmann | Kathrin Rupp | Martina C. Cornel | J. Loeber | M. Cornel | T. Rigter | G. Hoffmann | P. Burgard | S. Weinreich | J. Gerard Loeber | Peter Burgard | Tessel Rigter | Stephanie S. Weinreich | K. Rupp | L. Vittozzi | Georg F. Hoffmann | J. Loeber | M. Cornel | Stephanie S. Weinreich | Martina C. Cornel | S. Weinreich
[1] Mark S. Blumberg,et al. Evaluating Health Screening Procedures , 1957 .
[2] M. Petros. Revisiting the Wilson-Jungner criteria: How can supplemental criteria guide public health in the era of genetic screening? , 2011, Genetics in medicine : official journal of the American College of Medical Genetics.
[3] I. Harting,et al. Use of guidelines improves the neurological outcome in glutaric aciduria type I , 2010, Annals of neurology.
[4] Ja Wilson,et al. Principles and practice of screening for disease , 1968 .
[5] S. Rivkees,et al. Guidelines for the Development of Comprehensive Care Centers for Congenital Adrenal Hyperplasia: Guidance from the CARES Foundation Initiative , 2010, International journal of pediatric endocrinology.
[6] Grazyna Adamiak,et al. Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .
[7] P. V. van Dyck,et al. A Look at Newborn Screening: Today and Tomorrow , 2006, Pediatrics.
[8] S. Paisley,et al. Clinical-effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: A systematic review , 2004, International Journal of Technology Assessment in Health Care.
[9] O. Bodamer,et al. Expanded newborn screening in Europe 2007 , 2007, Journal of Inherited Metabolic Disease.
[10] M. Durán,et al. Diagnosis and management of glutaric aciduria type I – revised recommendations , 2011, Journal of Inherited Metabolic Disease.
[11] J. Gray,et al. Screening: Evidence and Practice , 2019 .
[12] Michael S. Watson,et al. Newborn Screening: Toward a Uniform Screening Panel and System—Executive Summary , 2006, Pediatrics.
[13] A. Kemper,et al. Completeness and Complexity of Information Available to Parents From Newborn-Screening Programs , 2005, Pediatrics.
[14] O. Sommerburg,et al. European best practice guidelines for cystic fibrosis neonatal screening. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[15] Janice Fletcher,et al. Expanded Newborn Screening: Outcome in Screened and Unscreened Patients at Age 6 Years , 2009, Pediatrics.
[16] M. Leichsenring,et al. Efficacy and outcome of expanded newborn screening for metabolic diseases - Report of 10 years from South-West Germany * , 2011, Orphanet journal of rare diseases.
[17] A. Kemper,et al. What questions should newborn screening long-term follow-up be able to answer? A statement of the US Secretary for Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children , 2011, Genetics in Medicine.
[18] C. Rembold. Number needed to screen: development of a statistic for disease screening , 1998, BMJ.
[19] B. Wilcken. Newborn screening: how are we travelling, and where should we be going? , 2011, Journal of Inherited Metabolic Disease.
[20] R. Pollitt,et al. Introducing new screens: Why are we all doing different things? , 2007, Journal of Inherited Metabolic Disease.
[21] N. Holtzman. Newborn screening for inborn errors of metabolism. , 1978, Pediatric clinics of North America.
[22] J. Loeber,et al. Neonatal screening in Europe; the situation in 2004 , 2007, Journal of Inherited Metabolic Disease.
[23] D. Taruscio,et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2 – From screening laboratory results to treatment, follow-up and quality assurance , 2012, Journal of Inherited Metabolic Disease.
[24] A. Ribes,et al. Natural History, Outcome, and Treatment Efficacy in Children and Adults with Glutaryl-CoA Dehydrogenase Deficiency , 2006, Pediatric Research.